electroCore, Inc. (ECOR)

NASDAQ: ECOR · IEX Real-Time Price · USD
7.00
-0.12 (-1.69%)
At close: May 17, 2024, 3:53 PM
6.92
-0.08 (-1.14%)
After-hours: May 17, 2024, 7:23 PM EDT
-1.69%
Market Cap 42.04M
Revenue (ttm) 18.69M
Net Income (ttm) -16.47M
Shares Out 6.01M
EPS (ttm) -2.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,148
Open 7.16
Previous Close 7.12
Day's Range 7.00 - 7.32
52-Week Range 3.83 - 8.08
Beta 0.92
Analysts Strong Buy
Price Target 15.00 (+114.29%)
Earnings Date May 8, 2024

About ECOR

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general healt... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Jun 22, 2018
Employees 68
Stock Exchange NASDAQ
Ticker Symbol ECOR
Full Company Profile

Financial Performance

In 2023, electroCore's revenue was $16.03 million, an increase of 86.57% compared to the previous year's $8.59 million. Losses were -$18.83 million, -15.02% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for ECOR stock is "Strong Buy" and the 12-month stock price forecast is $15.0.

Price Target
$15.0
(114.29% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

electroCore Announces First Quarter 2024 Financial Results

Record first quarter 2024 net sales of $5.4 million, an increase of 96% over first quarter 2023 Company to host a conference call and webcast today, May 8, 2024 at 4:30 PM EST

10 days ago - GlobeNewsWire

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

ROCKAWAY, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that on May 1, 2024,...

15 days ago - GlobeNewsWire

electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024

ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results...

17 days ago - GlobeNewsWire

Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion

ROCKAWAY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of its...

18 days ago - GlobeNewsWire

electroCore Announces the Launch of Truvaga Plus® for General Wellness

ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consume...

5 weeks ago - GlobeNewsWire

electroCore Expands Intellectual Property Portfolio

ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue n...

6 weeks ago - GlobeNewsWire

electroCore Announces Fourth Quarter and Full Year 2023 Financial Results

Record full year 2023  net sales of $ 16.0 million increased 87%  over $8.6  million for the full year 2022

2 months ago - GlobeNewsWire

electroCore to Participate in Upcoming Investor Conferences

ROCKAWAY, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company's Chief Strategy O...

2 months ago - GlobeNewsWire

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024

ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial resul...

2 months ago - GlobeNewsWire

electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology

ROCKAWAY, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Tradema...

5 months ago - GlobeNewsWire

Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023

ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company's Chief Medical Off...

6 months ago - GlobeNewsWire

electroCore Announces Third Quarter 2023 Financial Results

Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5 million  C...

6 months ago - GlobeNewsWire

electroCore to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

ROCKAWAY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, is...

6 months ago - GlobeNewsWire

Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting

Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia Clinical Trial suggests nVNS can reduce the use of rescue...

7 months ago - GlobeNewsWire

electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue

ROCKAWAY, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue...

7 months ago - GlobeNewsWire

electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology

ROCKAWAY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Tradema...

7 months ago - GlobeNewsWire

Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress

“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH)

7 months ago - GlobeNewsWire

electroCore to Announce Third Quarter Financial Results on Wednesday, November 8

ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial result...

7 months ago - GlobeNewsWire

electroCore to Participate in the Lytham Partners Fall 2023 Virtual Investor Conference

ROCKAWAY, N.J., Oct. 05, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, wi...

8 months ago - GlobeNewsWire

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)

Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in p...

8 months ago - GlobeNewsWire

electroCore to Participate in the LD Micro Main Event XVI Conference

ROCKAWAY, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, w...

8 months ago - GlobeNewsWire

electroCore to Present at iAccess Alpha's – Top 10 Best Ideas from the Buyside Virtual Conference

ROCKAWAY, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, w...

8 months ago - GlobeNewsWire

electroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

ROCKAWAY, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, w...

9 months ago - GlobeNewsWire

electroCore Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering

ROCKAWAY, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic and wellness company, today announced that it has been completely vindicated in the...

9 months ago - GlobeNewsWire

electroCore Announces Second Quarter 2023 Financial Results

Record second quarter 2023 net sales of $3.6 million, an increase of approximately 65% over second quarter 2022 Company to host a conference call and webcast today, August 9, 2023 at 4:30 PM EDT ROCKA...

10 months ago - GlobeNewsWire